Celldex Therapeutics reported $35.73M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Agenus USD 35M 32M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celldex Therapeutics USD 35.73M 6.86M Mar/2026
Glaxosmithkline GBP 3.3B 303M Sep/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 1.7B 561M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025